Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

More than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t generate much sales momentum behind the product. Its latest gambit is ...

The rapid addition of small interfering RNA therapy to usual care after a recent ACS helps more patients achieve recommended ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...